In a patient using the levonorgestrel intrauterine system (Mirena) who develops new or worsening depressive symptoms, what is the appropriate management?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Management of Depression in Mirena (LNG-IUS) Users

If a patient develops new or worsening depressive symptoms while using Mirena, the device should be removed if the patient desires, and alternative non-hormonal contraception should be offered. The evidence strongly supports a dose-dependent relationship between levonorgestrel exposure and depression risk, with symptoms typically resolving within weeks after removal.

Evidence for the Association

The relationship between Mirena and depression is increasingly well-established:

  • Dose-dependent risk: A 2024 Danish national cohort study of 149,200 women demonstrated that high-dose LNG-IUS users (like Mirena 52mg) had a 52% increased risk of incident depression compared to low-dose users (RR: 1.52,95% CI: 1.30-1.74), with 1-year absolute risk of 1.84% 1. This dose-response relationship strengthens the causal inference.

  • Symptom onset and reversibility: Depression typically develops within 3 months of insertion 2. Critically, symptoms resolve within weeks after device removal in all documented cases 2.

  • Broader evidence: A 2023 systematic review found that while data quality varies, many studies report psychiatric symptoms associated with LNG-IUDs, predominantly depression and concerning reports of suicidality 3.

Clinical Management Algorithm

Step 1: Assess Temporal Relationship

  • Determine when depressive symptoms began relative to Mirena insertion
  • Symptoms appearing within 3 months of insertion are highly suggestive of device-related depression 2

Step 2: Explore Patient Goals

Following the 2024 CDC contraceptive guidelines framework 4:

If patient wants to continue Mirena:

  • Provide counseling about the established association between LNG-IUS and depression
  • Explain that symptoms are unlikely to improve while device remains in place
  • Consider trial of antidepressant therapy per standard depression management 5
  • Caution: This approach may expose the patient to ongoing hormonal effects and delay symptom resolution

If patient desires removal (recommended approach):

  • Remove the device promptly
  • Counsel that symptom improvement typically occurs within weeks 2
  • Offer alternative contraceptive methods, prioritizing non-hormonal options (copper IUD, barrier methods)
  • If hormonal contraception is still desired, note that some patients tolerate different progestin formulations after recovery 2, though this carries risk of recurrence

Step 3: Rule Out Other Causes

While pursuing removal, evaluate for:

  • Pre-existing or family history of depression (though this does not exclude device-related worsening)
  • Other medical conditions (thyroid disorders, anemia from bleeding changes)
  • Psychosocial stressors
  • Medication interactions

Step 4: Post-Removal Monitoring

  • Follow up within 2-4 weeks after removal to assess symptom trajectory
  • If symptoms persist beyond 4-6 weeks post-removal, treat as primary depression 5
  • Document the adverse event

Critical Pitfalls to Avoid

Do not dismiss the patient's concerns: The association between LNG-IUS and depression is supported by high-quality observational data, including a dose-response relationship 1. While observational studies cannot prove causation definitively, the consistency of findings and rapid symptom resolution after removal support a causal relationship.

Do not delay removal in symptomatic patients who request it: The 2024 CDC guidelines explicitly state that if a patient desires removal at any time, the method should be removed 4. Symptom resolution is typically rapid after removal 2.

Do not assume all progestins will cause the same reaction: While cross-reactivity can occur (three of seven patients in one series had experienced mood problems with another progestin 2), two patients successfully used different progestin methods after recovery. However, non-hormonal options should be prioritized.

Be aware of severe presentations: One case report documented cognitive symptoms severe enough to mimic frontotemporal dementia, which resolved after LNG-IUS removal 6. While rare, this illustrates the potential severity of neuropsychiatric effects.

Special Considerations

Adolescents and young women: The depression risk appears higher in younger users, with one study reporting HR of 1.97 in this population 7. Exercise particular caution and close monitoring in this age group.

Pre-existing mental health conditions: Recent evidence suggests that women with established mood disorders may actually tolerate hormonal contraception better than previously thought, with some studies showing stable or improved symptoms 8. However, new-onset or worsening symptoms still warrant device removal if desired by the patient.

Suicidality concerns: Multiple studies have reported associations with suicidal ideation 3, 7. Any suicidal thoughts warrant immediate psychiatric evaluation and strong consideration for device removal.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.